Document resource
Thrombospondin 2 (TSP-2), a member of the thrombospondin family of secreted glycoproteins, has been reported to be associated with the severity of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease (MASLD).1 2 Serum TSP-2 has shown potential as a biomarker for the diagnosis of advanced fibrosis (AF) and at-risk metabolic dysfunction-associated steatohepatitis (MASH) (ARM) in a large, multicentre European cohort of patients with MASLD.1 However, data regarding its clinical utility for predicting liver fibrosis in chronic liver diseases other than MASLD remain limited. Although MASLD has become the most common cause of chronic liver disease and continues to rise in prevalence, viral hepatitis, particularly chronic hepatitis B (CHB), remains a major global health burden, especially in Asian and African regions.3 4 Given the critical importance of non-invasive assessment of liver fibrosis for the clinical management of CHB,5 we evaluated the predictive value of serum TSP-2 levels for liver fibrosis in patients with CHB.